These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 25930159)

  • 1. Human polyomavirus JC replication and non-coding control region analysis in multiple sclerosis patients under natalizumab treatment.
    Pietropaolo V; Bellizzi A; Anzivino E; Iannetta M; Zingaropoli MA; Rodio DM; Morreale M; Pontecorvo S; Francia A; Vullo V; Palamara AT; Ciardi MR
    J Neurovirol; 2015 Dec; 21(6):653-65. PubMed ID: 25930159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JC virus urinary excretion and seroprevalence in natalizumab-treated multiple sclerosis patients.
    Delbue S; Elia F; Carloni C; Pecchenini V; Franciotta D; Gastaldi M; Colombo E; Signorini L; Carluccio S; Bellizzi A; Bergamaschi R; Ferrante P
    J Neurovirol; 2015 Dec; 21(6):645-52. PubMed ID: 25052191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Which is the best PML risk stratification strategy in natalizumab-treated patients affected by multiple sclerosis?
    Prezioso C; Zingaropoli MA; Iannetta M; Rodio DM; Altieri M; Conte A; Vullo V; Ciardi MR; Palamara AT; Pietropaolo V
    Mult Scler Relat Disord; 2020 Jun; 41():102008. PubMed ID: 32087593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natalizumab-treated patients at high risk for PML persistently excrete JC polyomavirus.
    Werner MH; Huang D
    J Neurovirol; 2016 Dec; 22(6):871-875. PubMed ID: 27198748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JC Virus-DNA Detection Is Associated with CD8 Effector Accumulation in Peripheral Blood of Patients with Multiple Sclerosis under Natalizumab Treatment, Independently from JC Virus Serostatus.
    Zingaropoli MA; Iannetta M; Pontecorvo S; Anzivino E; Prezioso C; Rodio DM; Morreale M; D'Abramo A; Oliva A; Lichtner M; Cortese A; Frontoni M; Pietropaolo V; Francia A; Mastroianni CM; Vullo V; Ciardi MR
    Biomed Res Int; 2018; 2018():5297980. PubMed ID: 29682547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JC polyomavirus expression and bell-shaped regulation of its SF2/ASF suppressor during the follow-up of multiple sclerosis patients treated with natalizumab.
    Uleri E; Ibba G; Piu C; Caocci M; Leoni S; Arru G; Serra C; Sechi G; Dolei A
    J Neurovirol; 2017 Apr; 23(2):226-238. PubMed ID: 27812788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human Polyomavirus JC monitoring and noncoding control region analysis in dynamic cohorts of individuals affected by immune-mediated diseases under treatment with biologics: an observational study.
    Bellizzi A; Anzivino E; Rodio DM; Cioccolo S; Scrivo R; Morreale M; Pontecorvo S; Ferrari F; Di Nardo G; Nencioni L; Carluccio S; Valesini G; Francia A; Cucchiara S; Palamara AT; Pietropaolo V
    Virol J; 2013 Sep; 10():298. PubMed ID: 24079660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients.
    Basnyat P; Hagman S; Kolasa M; Koivisto K; Verkkoniemi-Ahola A; Airas L; Elovaara I
    Mult Scler Relat Disord; 2015 Jul; 4(4):334-8. PubMed ID: 26195052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of plasma exchange on serum anti-JC virus antibodies.
    Subramanyam M; Plavina T; Khatri BO; Fox RJ; Goelz SE
    Mult Scler; 2013 Jun; 19(7):912-9. PubMed ID: 23232602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JC virus viremia in interferon-beta -treated and untreated Italian multiple sclerosis patients and healthy controls.
    Delbue S; Guerini FR; Mancuso R; Caputo D; Mazziotti R; Saresella M; Ferrante P
    J Neurovirol; 2007; 13(1):73-7. PubMed ID: 17454451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis.
    Chalkias S; Dang X; Bord E; Stein MC; Kinkel RP; Sloane JA; Donnelly M; Ionete C; Houtchens MK; Buckle GJ; Batson S; Koralnik IJ
    Ann Neurol; 2014 Jun; 75(6):925-34. PubMed ID: 24687904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asymptomatic reactivation of JC virus in patients treated with natalizumab.
    Chen Y; Bord E; Tompkins T; Miller J; Tan CS; Kinkel RP; Stein MC; Viscidi RP; Ngo LH; Koralnik IJ
    N Engl J Med; 2009 Sep; 361(11):1067-74. PubMed ID: 19741227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of JC polyomavirus in stool samples of patients with multiple sclerosis despite high anti-JCV antibodies in serum.
    Schweitzer F; Ladwig A; Opala S; Laurent S; Schroeter M; Goelz S; Fink GR; Wieland U; Silling S; Warnke C
    Mult Scler Relat Disord; 2024 Jul; 87():105664. PubMed ID: 38735204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of JC virus DNA in blood and urine from natalizumab-treated patients.
    Rudick RA; O'Connor PW; Polman CH; Goodman AD; Ray SS; Griffith NM; Jurgensen SA; Gorelik L; Forrestal F; Sandrock AW; Goelz SE
    Ann Neurol; 2010 Sep; 68(3):304-10. PubMed ID: 20737514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of B-cell activating factor gene variants with serum anti-JCV antibody positivity in male patients with multiple sclerosis under natalizumab treatment: Implications for progressive multifocal leukoencephalopathy risk stratification.
    Skarlis C; Papadopoulos V; Raftopoulou S; Mavragani CP; Evangelopoulos ME
    J Neurol Sci; 2024 Jun; 461():123046. PubMed ID: 38761670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JCV detection in multiple sclerosis patients treated with natalizumab.
    Sadiq SA; Puccio LM; Brydon EW
    J Neurol; 2010 Jun; 257(6):954-8. PubMed ID: 20052484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring the John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients.
    Domínguez-Mozo MI; García-Montojo M; Arias-Leal A; García-Martínez Á; Santiago JL; Casanova I; Galán V; Arroyo R; Fernández-Arquero M; Alvarez-Lafuente R
    Eur J Neurol; 2016 Jan; 23(1):182-9. PubMed ID: 26498276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequencing and analysis of JC virus DNA from natalizumab-treated PML patients.
    Reid CE; Li H; Sur G; Carmillo P; Bushnell S; Tizard R; McAuliffe M; Tonkin C; Simon K; Goelz S; Cinque P; Gorelik L; Carulli JP
    J Infect Dis; 2011 Jul; 204(2):237-44. PubMed ID: 21673034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.
    Vennegoor A; van Rossum JA; Polman CH; Wattjes MP; Killestein J
    Mult Scler; 2015 Oct; 21(12):1600-3. PubMed ID: 25662344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-occurrence of two cases of progressive multifocal leukoencephalopathy in a natalizumab "infusion group".
    Havla J; Berthele A; Kümpfel T; Krumbholz M; Jochim A; Kronsbein H; Ryschkewitsch C; Jensen P; Lippmann K; Hemmer B; Major E; Hohlfeld R
    Mult Scler; 2013 Aug; 19(9):1213-5. PubMed ID: 23124790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.